Description

FILITRA 20 MG

Indications

FILITRA 20 MG is primarily indicated for the treatment of erectile dysfunction (ED) in adult men. ED is characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. FILITRA 20 MG may also be used in the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical worsening.

Mechanism of Action

The active ingredient in FILITRA 20 MG is Vardenafil, a phosphodiesterase type 5 (PDE5) inhibitor. Vardenafil works by inhibiting the enzyme PDE5, which is responsible for the degradation of cyclic guanosine monophosphate (cGMP). cGMP is a crucial mediator in the process of penile erection. When sexual stimulation occurs, nitric oxide (NO) is released, leading to increased levels of cGMP. By inhibiting PDE5, FILITRA 20 MG enhances the effects of NO, resulting in prolonged vasodilation and increased blood flow to the penis, thereby facilitating an erection. In the case of PAH, the increased levels of cGMP lead to vasodilation of pulmonary and systemic arterial vascular beds, reducing pulmonary vascular resistance and improving exercise capacity.

Pharmacological Properties

FILITRA 20 MG is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The bioavailability of Vardenafil is approximately 15%, and its effects can last for up to 5 hours. The elimination half-life of Vardenafil is about 4 to 5 hours, allowing for once-daily dosing in most patients. The drug is metabolized primarily in the liver via the cytochrome P450 enzyme system, particularly CYP3A4. Renal excretion is the main route for the elimination of metabolites.

Contraindications

FILITRA 20 MG is contraindicated in patients who are hypersensitive to Vardenafil or any of the excipients in the formulation. It should not be used in conjunction with nitrates or nitric oxide donors, as this combination can lead to severe hypotension. Additionally, FILITRA is contraindicated in patients with severe hepatic impairment, severe renal impairment, or those who are on medications that are potent CYP3A4 inhibitors.

Side Effects

Common side effects associated with FILITRA 20 MG include headache, flushing, nasal congestion, dyspepsia, and dizziness. These side effects are generally mild to moderate in severity and tend to resolve with continued use. Serious adverse effects, although rare, can include priapism (prolonged erection), sudden vision loss, and sudden hearing loss. Patients experiencing any severe or persistent side effects should seek medical attention promptly.

Dosage and Administration

The recommended starting dose of FILITRA 20 MG for erectile dysfunction is one tablet taken orally approximately 30 to 60 minutes before sexual activity. The maximum recommended dosing frequency is once per day. Depending on individual efficacy and tolerability, the dose may be adjusted to 10 MG or 20 MG. For the treatment of pulmonary arterial hypertension, the usual starting dose is 5 MG taken three times a day, with adjustments made based on clinical response and tolerability.

Interactions

FILITRA 20 MG may interact with several medications, particularly those that affect the CYP3A4 enzyme system. Co-administration with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, and certain protease inhibitors, can increase plasma concentrations of Vardenafil, leading to an increased risk of side effects. Nitrates and nitric oxide donors should not be used concurrently due to the risk of severe hypotension. Caution is also advised when using FILITRA with alpha-blockers, as this combination may lead to symptomatic hypotension.

Precautions

Before prescribing FILITRA 20 MG, healthcare providers should conduct a thorough medical history and physical examination to identify any underlying cardiovascular conditions. Patients with a history of cardiovascular disease, such as myocardial infarction, stroke, or arrhythmias, should be evaluated carefully before initiating treatment. Additionally, FILITRA should be used with caution in patients with anatomical deformities of the penis, such as Peyronie’s disease, or those predisposed to priapism. Regular follow-up is recommended to monitor the patient’s response to treatment and any potential side effects.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of FILITRA 20 MG in the treatment of erectile dysfunction. In randomized, double-blind, placebo-controlled trials, patients reported significant improvements in erectile function as measured by the International Index of Erectile Function (IIEF) and the Erectile Function Domain (EFD) scores. Moreover, studies have shown that FILITRA is effective across various populations, including those with diabetes and post-prostatectomy patients. For pulmonary arterial hypertension, clinical trials have indicated that FILITRA improves exercise capacity and quality of life, with a favorable safety profile.

Conclusion

FILITRA 20 MG is an effective treatment option for erectile dysfunction and pulmonary arterial hypertension. Its mechanism of action as a PDE5 inhibitor enhances erectile function and improves exercise capacity in patients with PAH. While generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. A thorough medical evaluation and ongoing monitoring are crucial to ensure safe and effective use of FILITRA 20 MG.